Use of COVID-19 Vaccines in the United States

Interim Clinical Considerations

Summary of recent changes (last updated May 20, 2022):
  • New guidance for use of a Pfizer-BioNTech COVID-19 Vaccine booster dose in children ages 5–11 years
  • Updated guidance that the following people should receive a second COVID-19 booster dose:
    • People ages 12 years and older who are moderately or severely immunocompromised
    • People ages 50 years and older
  • Updated guidance for people who are moderately or severely immunocompromised and are treated with B-cell-depleting therapies
  • Clarification of COVID-19 vaccination guidance for multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A)
  • Updated guidance for primary series vaccination after SARS-CoV-2 infection
More about the Interim Clinical Considerations

See the FAQ page for answers to commonly asked questions about the Interim Clinical Considerations.

Page last reviewed: May 23, 2022